Answers are grounded in this paper and cite their sources.
This randomized trial identifies genetic markers linked to drug resistance in malaria treatment failures, suggesting effective antimalarial strategies.
allele was 67.03% and 97.70%, respectively. In contrast, the mutant types CVIET and 86Y were found at 32.97% and 2.3%, respectively. The high prevalence of the CVMNK wild haplotype suggests that the parasites remain sensitive to chloroquine, while the low prevalence of the 86Y mutants indicates continued effectiveness of amodiaquine. Furthermore, the low prevalence of strains exhibiting the combination of CVIET and 86Y suggests that the use of multiple antimalarials is valuable for resistance control. Notably, none of the relapse cases carried the 86Y mutation or the combination of 86Y and CVIET.
No takes yet. Share an insight, caveat, or question.
Magatte Ndiaye (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: